60 Degrees Pharmaceuticals, Inc. (SXTP)
Nasdaq · Healthcare · Biotechnology
$1.44+3.60%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $5.1M
- 52-week range
- $0.84 – $8.62
- 52-week change
- −76.03%
- EPS (trailing)
- −$5.34
Fiscal year to Dec 2025
- Revenue
- $1.0M (+65.50%)
- Net income
- −$7.4M
- Operating margin
- −771.6%
- Diluted EPS
- −$11.73
- Free cash flow
- −$7.0M
From the company’s annual report on SEC EDGAR.
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.
Headquarters: Washington, United States · 3 employees · 60degreespharma.com